scholarly journals Interferon-beta: treatment option against COVID-19

2020 ◽  
Vol 6 (3) ◽  
Author(s):  
Faiz Ul Haq ◽  
Muhammad Usman Khan ◽  
Ayesha Muazzam ◽  
Hajrah Farooq ◽  
Javeria Iqbal ◽  
...  
Keyword(s):  
Treatment Option ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Final Analysis ◽  
Significant Activity ◽  
Interferon Β ◽  
Wholesale Market ◽  
Current Review ◽  
Novel Coronavirus ◽  
Approved Drugs

In December 2019, an increasing number of cases of novel coronavirus (2019-nCoV) that were linked to seafood wholesale market have identified in Wuhan, China. Taxonomist declared 2019-nCoV as severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) and the disease termed as COVID-19. Importantly, there is no approved drugs or vaccine against SARS-CoV-2. Current review is related to address treatment option for COVID-19. Interferon-β have shown significant activity against previous outbreak of SARS-CoV and MERS-CoV. Faced with an ongoing pandemic of SARS-CoV-2 and lack of effective treatment options, identifying compounds with antiviral activity has become a high priority. Efficacy of these treatments is still unclear. Therefore, final analysis is important to develop better treatment strategies for ongoing pandemic.

scholarly journals Effectiveness comparisons of various therapies for FIGO stage IB2/IIA2 cervical cancer: a Bayesian network meta-analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jing Cheng ◽  
Beibei Liu ◽  
Biao Wang ◽  
Xicui Long ◽  
Zhihong Li ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Bayesian Network ◽  
Cancer Patients ◽  
Radical Surgery ◽  
Meta Analysis ◽  
Treatment Options ◽  
Female Genital Tract ◽  
Treatment Strategies ◽  
Final Analysis ◽  
Phase Iii

Abstract Background Cervical cancer is a common malignancy of the female genital tract. Treatment options for cervical cancer patients diagnosed at FIGO (2009) stage IB2 and IIA2 remains controversial. Methods We perform a Bayesian network meta-analysis to directly or indirectly compare various interventions for FIGO (2009) IB2 and IIA2 disease, in order to improve our understand of the optimal treatment strategy for these women. Three databases were searched for articles published between 1971 and 2020. Data on included study characteristics, outcomes, and risk of bias were abstracted by two reviewers. Results Seven thousand four hundred eighty-six articles were identified. Thirteen randomized controlled trials of FIGO (2009) IB2 and IIA2 cervical cancer patients were included in the final analysis. These trials used six different interventions: concomitant chemoradiotherapy (CCRT), radical surgery (RS), radical surgery following chemoradiotherapy (CCRT+RS), neoadjuvant chemotherapy followed by radical surgery (NACT+RS), adjuvant radiotherapy followed by Radical surgery (RT + RS), radiotherapy alone (RT).SUCRA ranking of OS and Relapse identified CCRT+RS and CCRT as the best interventions, respectively. Systematic clustering analysis identified the CCRT group as a unique cluster. Conclusion These data suggest that CCRT may be the best approach for improving the clinical outcome of cervical cancer patients diagnosed at FIGO (2009) stage IB2/IIA2. Phase III randomized trials should be performed in order to robustly assess the relative efficacy of available treatment strategies in this disease context.

scholarly journals Emerging Prevention and Treatment Strategies to Control COVID-19

Pathogens ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 501 ◽  
Author(s):  
Vipul K. Singh ◽  
Abhishek Mishra ◽  
Shubhra Singh ◽  
Premranjan Kumar ◽  
Manisha Singh ◽  
...  
Keyword(s):  
Early Stage ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Clinical Development ◽  
Definitive Treatment ◽  
Prevention Therapy ◽  
Potential Alternative ◽  
Novel Coronavirus ◽  
Global Threat ◽  
New Vaccines

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has now become a serious global threat after inflicting more than 8 million infections and 425,000 deaths in less than 6 months. Currently, no definitive treatment or prevention therapy exists for COVID-19. The unprecedented rise of this pandemic has rapidly fueled research efforts to discover and develop new vaccines and treatment strategies against this novel coronavirus. While hundreds of vaccines/therapeutics are still in the preclinical or early stage of clinical development, a few of them have shown promising results in controlling the infection. Here, in this review, we discuss the promising vaccines and treatment options for COVID-19, their challenges, and potential alternative strategies.

scholarly journals A Review of Updates on Vaccines and Treatment Options for Covid-19

2021 ◽  
Vol VI (I) ◽  
pp. 1-9
Author(s):  
Naiha Tahir ◽  
Ayema Rehman ◽  
Muhammad Zain ◽  
Mubashir Rehman
Keyword(s):  
Focal Point ◽  
Treatment Options ◽  
The Novel ◽  
Wholesale Market ◽  
Current Management ◽  
Enveloped Virus ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
In The Beginning ◽  
The City

The novel Coronavirus knew as Covid 19 or SARS-CoV-2, is a newly discovered virus responsible for the huge global pandemic infecting the human race at a deadly pace. This is an RNA enveloped virus that targets the human respiratory system severely while damaging other major systems. Covid 19 pandemic is similar to the severe acute respiratory syndrome related coronavirus (SARS-CoV) endemic and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), but this one is spreading at a fire-speed. The outbreak was known as pneumonia in the beginning; however, it became a threat later on, owing to its high contagion rate. The origin of this virus was sought to be from the seafood wholesale market, very popular in the city of Wuhan. This review has been put together to overview the disease, its etiology, clinical features and treatment methods. The focal point of this review is to highlight the current management of this disease.

scholarly journals Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model

2020 ◽  
Author(s):  
Bo Ram Beck ◽  
Bonggun Shin ◽  
Yoonjung Choi ◽  
Sungsoo Park ◽  
Keunsoo Kang
Keyword(s):  
Deep Learning ◽  
Effective Treatment ◽  
Drug Target ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Interaction Model ◽  
Antiviral Drugs ◽  
Inhibitory Potency ◽  
Target Interaction ◽  
Novel Coronavirus

AbstractThe infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing. In this study, we used our pretrained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of 2019-nCoV. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing a inhibitory potency with Kd of 94.94 nM against the 2019-nCoV 3C-like proteinase, followed by efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of 2019-nCoV with an inhibitory potency with Kd < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.

scholarly journals Insight into ongoing and emerging therapeutic options for COVID-19: a review

2020 ◽  
Vol 9 (11) ◽  
pp. 1749
Author(s):  
Shweta Singla ◽  
Amanjot Kaur ◽  
Mandeep Kaur
Keyword(s):  
Care Management ◽  
Treatment Options ◽  
Sufficient Evidence ◽  
Severe Respiratory Failure ◽  
Intensive Care Management ◽  
Mild Disease ◽  
Current Review ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Insight Into

ABSTRACTThe outbreak of novel coronavirus (COVID-19) has evolved into a global pandemic and has posed significant threats to health and the economy worldwide. It can manifest from mild disease to severe respiratory failure requiring intensive care management. Currently, there is no sufficient evidence that any existing drugs can effectively treat SARS-CoV-2 pneumonia though supportive care remains the mainstay of treatment. However, there are many ongoing clinical trials of potential anti-COVID-19 therapies including the vaccines. In the current review, we Summarized the information available about COVID-19 medications, and treatment options.

Non-invasive ultrasound-based imaging of atherosclerosis

VASA ◽  
2019 ◽  
Vol 48 (2) ◽  
pp. 126-133 ◽  
Author(s):  
Mathias Kaspar ◽  
Iris Baumgartner ◽  
Daniel Staub ◽  
Heinz Drexel ◽  
Christoph Thalhammer
Keyword(s):  
Large Population ◽  
Treatment Strategies ◽  
Intima Media Thickness ◽  
Scientific Work ◽  
Flow Mediated Dilation ◽  
Non Invasive ◽  
Grey Scale ◽  
Current Review ◽  
Appropriate Treatment ◽  
Contrast Enhanced

Abstract. Early detection of vascular damage in atherosclerosis and accurate assessment of cardiovascular risk factors are the basis for appropriate treatment strategies in cardiovascular medicine. The current review focuses on non-invasive ultrasound-based methods for imaging of atherosclerosis. Endothelial dysfunction is an accepted early manifestation of atherosclerosis. The most widely used technique to study endothelial function is non-invasive, flow-mediated dilation of the brachial artery under high-resolution ultrasound imaging. Although an increased intima-media thickness value is associated with future cardiovascular events in several large population studies, systematic use is not recommended in clinical practice for risk assessment of individual persons. Carotid plaque analysis with grey-scale median, 3-D ultrasound or contrast-enhanced ultrasound are promising techniques for further scientific work in prevention and therapy of generalized atherosclerosis.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

Targeting COVID-19 in Parkinson’s patients: Drugs repurposed.

2020 ◽  
Vol 27 ◽  
Author(s):  
Firoz Anwar ◽  
Salma Naqvi ◽  
Fahad A. Al-Abbasi ◽  
Nauroz Neelofar ◽  
Vikas Kumar ◽  
...  
Keyword(s):  
Day Treatment ◽  
Treatment Options ◽  
Developed Countries ◽  
Methyl Transferase ◽  
Comt Inhibitors ◽  
Mao B ◽  
Pharmacokinetic Properties ◽  
Us Fda ◽  
Approved Drugs ◽  
Fda Approved Drugs

: The last couple of months have witnessed the world in a state of virtual standstill. The SARS-CoV-2 virus has overtaken globe to economic and social lockdown. Many patients with COVID-19 have compromised immunity, especially in an aged population suffering from Parkinson disease (PD). Alteration in dopaminergic neurons or deficiency of dopamine in PD patients is the most common symptoms affecting 1% population above the age of 60 years. The compromised immune system and inflammatory manifestation in PD patients make them an easy target. The most common under trial drugs for COVID-19 are Remdesivir, Favipiravir, Chloroquine and Hydroxychloroquine, Azithromycin along with adjunct drugs like Amantadine with some monoclonal antibodies. : Presently, clinically US FDA approved drugs in PD includes Levodopa, catechol-O-methyl transferase (COMT) inhibitors, (Entacapone and Tolcapone), Dopamine agonists (Bromocriptine, Ropinirole, Pramipexole, and Rotigotine), Monoamine oxidase B (MAO-B) inhibitors (Selegiline and Rasagiline), Amantadine and Antimuscarinic drugs. The drugs have established mechanism of action on PD patients with known pharmacodynamics and pharmacokinetic properties along with dose and adverse effects. : Conclusion and relevance of this review focus on the drugs that can be tried for the PD patients with SAR CoV-2 infection, in particular, Amantadine approved by all developed countries a common drug possessing both antiviral properties by downregulation of CTSL, lysosomal pathway disturbance and change in pH necessary to uncoat the viral proteins and antiParkinson properties. The significant prognostic adverse effect of SARS-CoV-2 on PD and the present-day treatment options, clinical presentation and various mechanism is warrant need of the hour.

Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients

2019 ◽  
Vol 21 (10) ◽  
pp. 734-748 ◽  
Author(s):  
Baoling Guo ◽  
Qiuxiang Zheng
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Drug Response ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Cancer Resistance ◽  
Lung Cancer Patients ◽  
Bayes Algorithm

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

The Current Outbreak of COVID-19 with reference to India

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Harshita Gupta
Keyword(s):  
Medical Research ◽  
Preventive Measures ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Highly Pathogenic ◽  
Indian Council ◽  
Current Outbreak ◽  
Novel Coronavirus ◽  
Bat Coronavirus ◽  
Viral Outbreak

Abstract:: This review summarizes the outbreak of viruses causing the fatal disease which is highly pathogenic and human to human transmittable and it first emerges in Wuhan, China and now this epidemic situation becomes worldwide. A novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus(SARS-CoV)-2 belongs to β-coronavirus genera which were originated in bats due to highly identical genome with bat coronavirus. This review highlights the Indian Council of Medical Research, India study which determined the detection of pathogenic coronavirus in two species of Indian bats. Indian Council of Medical Research, India has successfully isolated the COVID-19 virus strain which was the first step towards diagnosis and the development of vaccines in the country. The outbreaks of coronavirus received worldwide attention for overcoming the challenges faced during this current pandemic as there is no clinically approved antiviral drug or vaccine available, however, preventive measures and different treatments were taken to cope with this viral outbreak. In response to this global outbreak, this review tries to explain the Virology, Epidemiology, pathogenesis, and discusses the Diagnosis, treatment strategies of COVID-19. This review emphasizes the current update of knowledge about COVID-19.

Sign in / Sign up

Export Citation Format

Share Document